Company page

Tscan Therapeutics, Inc.

Tscan Therapeutics, Inc. is a public company traded under the ticker TCRX in the American market. The company has a market capitalization of approximately $60.1 million. Tscan focuses on developing innovative therapies for cancer and other diseases using its proprietary T-cell receptor platform.